Abstract
Twenty-three adolescents with psychotic disorders, aged from 13 to 18 years, participated in a 12-week open label trial (17
adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing
processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global
Impression and Positive and Negative Symptom Scale (P’s ≤ 0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed
on one executive function (P = 0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction
between quetiapine doses (>300 mg/day or <300 mg/day) and time, where lower doses showed more improvement in verbal short-term
memory (P = 0.048), inhibition abilities (P = 0.038) and positive symptoms (P = 0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12 weeks
of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition
abilities and verbal short-term memory) and on positive symptoms.
adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing
processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global
Impression and Positive and Negative Symptom Scale (P’s ≤ 0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed
on one executive function (P = 0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction
between quetiapine doses (>300 mg/day or <300 mg/day) and time, where lower doses showed more improvement in verbal short-term
memory (P = 0.048), inhibition abilities (P = 0.038) and positive symptoms (P = 0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12 weeks
of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition
abilities and verbal short-term memory) and on positive symptoms.
- Content Type Journal Article
- Category Original Paper
- Pages 1-14
- DOI 10.1007/s11126-011-9201-3
- Authors
- Sébastien Urben, Unité de Recherche, Service Universitaire de Psychiatrie de l’Enfant et de l’Adolescent (SUPEA), Centre Hospitalier Universitaire Vaudois (CHUV), Route du Bugnon 25A, 1011 Lausanne, Switzerland
- Pierre Baumann, Département de Psychiatrie, CHUV, Prilly-Lausanne, Switzerland
- Sandra Barcellona, Centre Thérapeutique de Jour pour Adolescents, SUPEA, CHUV, Lausanne, Switzerland
- Muriel Hafil, Centre Thérapeutique de Jour pour Adolescents, SUPEA, CHUV, Lausanne, Switzerland
- Ulrich Preuss, Kinder und Jugendpsychiatrische Poliklinik, Bern, Switzerland
- Claire Peter-Favre, Division de Neuropsychologie, CHUV, Lausanne, Switzerland
- Stéphanie Clarke, Division de Neuropsychologie, CHUV, Lausanne, Switzerland
- Olivier Halfon, SUPEA, CHUV, Lausanne, Switzerland
- Laurent Holzer, Centre Thérapeutique de Jour pour Adolescents, SUPEA, CHUV, Lausanne, Switzerland
- Journal Psychiatric Quarterly
- Online ISSN 1573-6709
- Print ISSN 0033-2720